Related Experiment Video
Updated: Sep 18, 2025
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Neuroprotective role of high dose Vitamin D supplementation in multiple sclerosis: Sub-analysis of the EVIDIMS trial
Enrique Gomez-Figueroa1, Carlos Moreno-Bernardino2, Priscilla Bäcker-Koduah3
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Neuroscience Clinical Research Center, Charitéplatz 1 10117 Berlin, Germany; Civil Hospital of Guadalajara, University of Guadalajara, 777 Coronel Calderon St 44280 Guadalajara, Mexico.
Background:
Previous evidence suggests that vitamin D may help with neurodegeneration in multiple sclerosis (MS). Considering this, the study aims to investigate whether higher-dose vitamin D supplementation in individuals with MS can lead to reduced atrophy, as measured by optical coherence tomography (OCT) and MRI structural outcomes. This objective builds upon the established notion of thalamic and brainstem atrophy as reliable markers of disease progression and the potential association between adequate vitamin D levels and improved visual outcomes in MS patients.
Objective:
To assess the impact of vitamin D as a neuroprotective intervention on visual and imaging biomarkers.
Method:
Participants enrolled in the EVIDIMS trial underwent an assessment to investigate the impact of high and low-dose vitamin D supplementation at 12 and 18 months using a nonparametric multiple contrast test procedure (MCTP). The primary outcomes included four MRI-radiological measures: change in the mean upper cervical cord area (MUCCA) and hippocampal, thalamic and brainstem volumes, and the visual system outcomes included assessment of the peripapillary retinal nerve fiber layer (pRNFL) thickness and macular combined ganglion cell and inner plexiform layer (GCIPL), and inner nuclear layer (INL).
Results:
MCTPs indicated that there were no statistically significant differences in the volumes of the thalamus, hippocampus, and brainstem, as well as in MUCCA, between the low and high-dose supplementation groups. Moreover, MTCPs only revealed a different thinning pattern in the INL at 18 months between the low versus high-dose treatment arm attributable to patients who suffered optic neuritis (NO), with no significant differences in neither pRNFL nor GCIPL.
Conclusion:
Vitamin D supplementation did not affect MS imaging parameters. However, future studies should thoroughly evaluate patient histories of attacks and endogenous vitamin D levels before inclusion in dose-related investigations.
Related Concept Videos
01:23Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
01:22Alzheimer's Disease: Treatment
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists